Business Wire

Leapmotor Debuts Global Product C10 and New Technologies at Munich, Launches Global Strategy

5.9.2023 20:27:00 EEST | Business Wire | Press release

Share

On September 4th, Leapmotor made its debut at the IAA MOBILITY 2023 (hereinafter referred to as "Munich Motor Show"), where the "LEAP TOGETHER: Shaping a Shared Technological Future" global press conference was held. The event comprehensively showcased the latest achievement of all-domain in-house development, Leap 3.0 architecture, and the inaugural global model, the C10.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905065907/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

C10 Model (Photo: Business Wire)

Leapmotor's Founder, Chairman, and CEO, Zhu Jiangming, emphasizes, “Leapmotor's globalization strategy encompasses the internationalization of both products and technology. Over 8 years of all-domain in-house development, Leapmotor has evolved from LEAP1.0 to LEAP3.0. With the arrival of our first global product based on LEAP3.0 architecture, the C10, all of Leapmotor's subsequent products will be designed and developed with a global mindset and adhere to global standards. In the next 2 years, Leapmotor will introduce 5 globally-oriented products in Europe, Asia-Pacific, the Middle East, the Americas, and other regions, offering intelligent mobility experiences to automotive consumers worldwide.”

As a technology-driven intelligent electric vehicle enterprise, Leapmotor remains steadfast in its commitment to all-domain in-house development of core technologies. With an unwavering commitment to shaping a shared future of intelligent mobility, Leapmotor remains devoted to delivering the finest smart mobility experience to all consumers.

Eight Years of All-domain In-house Development, LEAP 3.0 Embodies Cutting-Edge Intelligent Electric Technologies

Leap 3.0, with a central integrated electronic and electrical architecture as its core, encompasses several leading technologies, including CTC 2.0 (Cell-to-Chasis) technology, a latest oil-cooling electric drive, the intelligent cockpit with a Qualcomm Snapdragon 8295 chip, and a leading intelligent driving system. It is also built to global standards, and boasts an 88% interchangeability, imbuing each product with inherent intelligence, comfort, and safety traits.

Leapmotor's [Four-Leaf Clover] central integrated E/E architecture employs a central supercomputing platform, which seamlessly integrates the cockpit domain, pilot domain, power domain, and vehicle body domain, realizing the industry's pioneering convergence of these four domains. Furthermore, it enables vehicle-level seamless over-the-air (OTA) updates for five years. With over 500 reserved interfaces, it ensures Leapmotor to deliver an evolving and personalized driving experience.

Following last year's release of the package-less CTC technology, Leapmotor takes it a step further with CTC 2.0. This advanced technology eliminates modules, incorporates new safety features, and integrates a Battery Management System (BMS). This highly integrated battery-chassis equips the vehicle with attributes of extended range, enhanced safety, superior performance, and accelerated energy replenishment.

The latest oil-cooling electric drive features innovations that span from mid-voltage flat wire technology to high-voltage silicon carbide technology, offering power outputs ranging from 170kW to 250kW to accommodate both rear-wheel drive and all-wheel drive applications. The incorporation of high-voltage silicon carbide technology into the flat wire oil-cooling electric drive achieves a comprehensive efficiency of 92%, all while weighing only 76kg. This results in an ultra-compact and exceptionally powerful solution.

The Leapmotor intelligent cockpit system maximizes the capabilities of a Qualcomm Snapdragon 8295 chip, bestowing the cockpit with robust computing power and a seamless customer experience. The newly developed Leap OS intelligent desktop operating system caters to a multitude of driving scenarios, allowing customizable settings to accommodate diverse usage patterns.

At the intelligent driving level, the vehicle with Leap 3.0 is equipped with 30 high-performance perception hardware components, including LiDAR and an 8 million-pixel HD camera, delivering enhanced precision in perception. It is powered by an NVIDIA DRIVE Orin system-on-a-chip (SoC), which delivers 254 TOPS of computing to enable safe, high-speed and urban NAP intelligent-driving capabilities.

As an all-encompassing solution for intelligent electric vehicle technology, LEAP 3.0 stands as a prominent global leader in the field of intelligent electric vehicle technologies.

Leapmotor Initiates Globalization Strategy through Product Innovation and Technological Advancements

Leapmotor unveils C10 as the first model under LEAP3.0 architecture, marking its inaugural global strategic model. Embracing the signature design language of the Leapmotor family and leveraging the latest innovations of LEAP3.0, C10 embarks on an intelligent evolution to shape the future of mobility.

During the press conference, Mr. Zhu Jiangming stated, "Openness, co-creation, and global collaboration are key to achieving rapid proliferation of intelligent electric vehicles. Looking ahead, Leapmotor is not only an automobile manufacturer but also a comprehensive provider of intelligent electric vehicle solutions."

Globally, Leapmotor offers four different technology cooperation models, ranging from scratch to completion. Additionally, Leapmotor actively engages in strategic partnerships with world-renowned mobility ecosystem partners such as NVIDIA, ZF, Qualcomm, Bosch, and NXP.

The initiation of the global strategy is a critical step for Leapmotor as it leads the way with its competence of all-domain in-house development, driving the company's upward trajectory. It is also a demonstration of the synergy between brand strength, technological prowess, and influence.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tammy Hu
hu_huiling@leapmotor.com

Lexi Liu
liu_xinyun@leapmotor.com
+86 15601869865

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye